The stock of Ascendis Pharma A/S jumped 11% early Monday, after the biotech said the U.S. Food and Drug Administration has approved its Yorvipath as the first and only treatment for a rare endocrine disease.
Ascendis Pharma’s stock surges after FDA approval for first and only treatment for rare disease
